Kadsurenone
Based on 1 Customer Validation
Kadsurenone is a lignan with specific antagonistic activity against platelet-activating factor. Kadsurenone can be derived from the stem of Piper kadsura.
For research use only. We do not sell to patients.
- Purity: 99.78%
- CAS No.: 95851-37-9
- Formula: C21H24O5
- Molecular Weight:356.41
-
Storage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Platelet | IC50 |
0.12 μM
Compound: kadsurenone
|
Antiplatelet activity in rabbit platelets assessed as inhibition of PAF-induced platelet aggregation treated 5 mins before PAF challenge
Antiplatelet activity in rabbit platelets assessed as inhibition of PAF-induced platelet aggregation treated 5 mins before PAF challenge
|
[PMID: 19548690] |
| Platelet | IC50 |
0.153 μM
Compound: 25
|
Antiplatelet activity in rabbit platelets assessed as inhibition of platelet activating factor-induced platelet aggregation
Antiplatelet activity in rabbit platelets assessed as inhibition of platelet activating factor-induced platelet aggregation
|
[PMID: 19880317] |
| Platelet | IC50 |
38.1 μM
Compound: 25
|
Antiplatelet activity in rabbit platelets assessed as inhibition of adenosin 5'-diphosphate-induced platelet aggregation
Antiplatelet activity in rabbit platelets assessed as inhibition of adenosin 5'-diphosphate-induced platelet aggregation
|
[PMID: 19880317] |
| Platelet | IC50 |
5.61 μM
Compound: 25
|
Antiplatelet activity in rabbit platelets assessed as inhibition of arachidonic acid-induced platelet aggregation
Antiplatelet activity in rabbit platelets assessed as inhibition of arachidonic acid-induced platelet aggregation
|
[PMID: 19880317] |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley rats[1]
-
Dosage:0 and 30 mg/kg
-
Administration:IV
-
Result:Could go through hepatobiliary excretion.
Chemical Information
-
CAS No. 95851-37-9
-
Appearance Solid
-
Molecular Weight 356.41
-
Formula C21H24O5
-
Color White to off-white
-
SMILES
CO[C@]12C(O[C@H](C3=CC(OC)=C(C=C3)OC)[C@H]1C)=CC(C(CC=C)=C2)=O
-
Structure Classification
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
DMSO : 50 mg/mL (140.29 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 1.25 mg/mL (3.51 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1.25 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8058 mL | 14.0288 mL | 28.0576 mL | 70.1439 mL |
| 5 mM | 0.5612 mL | 2.8058 mL | 5.6115 mL | 14.0288 mL | |
| 10 mM | 0.2806 mL | 1.4029 mL | 2.8058 mL | 7.0144 mL | |
| 15 mM | 0.1871 mL | 0.9353 mL | 1.8705 mL | 4.6763 mL | |
| 20 mM | 0.1403 mL | 0.7014 mL | 1.4029 mL | 3.5072 mL | |
| 25 mM | 0.1122 mL | 0.5612 mL | 1.1223 mL | 2.8058 mL | |
| 30 mM | 0.0935 mL | 0.4676 mL | 0.9353 mL | 2.3381 mL | |
| 40 mM | 0.0701 mL | 0.3507 mL | 0.7014 mL | 1.7536 mL | |
| 50 mM | 0.0561 mL | 0.2806 mL | 0.5612 mL | 1.4029 mL | |
| 60 mM | 0.0468 mL | 0.2338 mL | 0.4676 mL | 1.1691 mL | |
| 80 mM | 0.0351 mL | 0.1754 mL | 0.3507 mL | 0.8768 mL | |
| 100 mM | 0.0281 mL | 0.1403 mL | 0.2806 mL | 0.7014 mL |
Kadsurenone Related Classifications
HY-N10663 Related Classifications
Powered by Bioz